Table of contents


On 26 August 2005, orphan designation (EU/3/05/301) was granted by the European Commission to Albany Regulatory Consulting Ltd, United Kingdom, for chimeric monoclonal antibody to shiga-toxin 1 and 2 for the treatment of shiga-toxin-producing bacterial infection.

The sponsorship was transferred to LFB-Biotechnologies, France, in March 2012.

The sponsorship was transferred to Albany Regulatory Consulting Ltd, United Kingdom, in June 2013.

The sponsorship was transferred to Taro Pharmaceuticals Europe B.V., The Netherlands, in February 2019.

Key facts

Active substance
Chimeric monoclonal antibody to shiga toxin 1 and 2
Disease / condition
Treatment of shiga-toxin-producing bacterial infection
Date of first decision
EU designation number

Sponsor's contact details

Taro Pharmaceuticals Europe B.V.
Naritaweg 165, Telestone 8G
1043BW Amsterdam
The Netherlands
Tel. +31 20 572 2341

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating